-
DMXAA (Vadimezan): Applied Cancer Workflows
2026-09-28
DMXAA (Vadimezan) gives cancer biology researchers a practical way to connect tumor vascular disruption, VEGFR2 signaling, apoptosis, and innate immune activation. This guide translates the compound’s preclinical profile into reproducible cell, tumor, and nanomedicine workflows with troubleshooting guidance.
-
Flubendazole in Breast Cancer Autophagy Workflows
2026-09-28
Use Flubendazole as an exploratory chemical perturbation alongside macrophage–extracellular-vesicle breast cancer models—not as a substitute for testing the miR-660 mechanism. This workflow pairs careful DMSO handling with autophagy-flux checks, migration assays, and controls that help separate compound effects from EV-driven signaling.
-
CB2R Activation Limits Iron-Overload Liver Injury
2026-09-27
Deng and colleagues report that cannabinoid receptor 2 (CB2R) activation reduces iron deposition, oxidative stress, and inflammation in an iron-overload mouse model. Their central mechanistic insight is a two-cell-type response: CB2R signaling suppresses STAT3-dependent hepcidin in hepatocytes while promoting Nrf2/FPN1 signaling in Kupffer cells.
-
Caspase-3/7 Inhibitor I in Apoptosis Workflows
2026-09-26
Use a reversible executioner-caspase inhibitor to test whether caspase-3/7 activity contributes to cell death—not simply accompanies it. A phase-resolved Candida krusei model offers a practical example, with workflow guidance for controls, orthogonal readouts, and troubleshooting.
-
Rucaparib Workflows for DNA Damage Research
2026-09-25
Use Rucaparib (AG-014699) to probe PARP-dependent repair, DNA damage persistence, and radiosensitization in carefully selected cancer models. This practical guide combines a controlled dose-and-radiation workflow with troubleshooting advice and a cautious framework for comparing DNA damage response findings with a recent study of Pol II degradation.
-
Azilsartan Medoxomil and AT1 Receptor Blockade
2026-09-25
This 2017 mini-review examines whether azilsartan medoxomil’s persistent AT1-receptor binding is reflected in its blood-pressure effects compared with other angiotensin receptor blockers. It summarizes receptor-binding, pharmacokinetic, and clinical evidence while highlighting that stronger blood-pressure reduction has not yet established a reduction in cardiovascular mortality.
-
EZ Cap™ CBEmax mRNA (m1Ψ): Evidence & Use
2026-09-24
EZ Cap™ CBEmax mRNA (m1Ψ) is a research-use cytosine base-editor mRNA product listed by APExBIO. A mouse-embryo study found excess variants with BE4, but it did not test R1044, so its results inform assay design rather than establish this product’s performance.
-
Peroxynitrite, ER Stress, and Cardiac I/R Injury
2026-09-24
Liu et al. describe how hyperhomocysteinemia can amplify cardiac microvascular ischemia–reperfusion injury through peroxynitrite-driven ER stress and IP3R-mediated calcium transfer to mitochondria. Their cell and rat models link calcium dysregulation to mitochondrial injury and endothelial necroptosis, while pharmacological IP3R inhibition improved cardiac outcomes in the rat model.
-
Everolimus (RAD001): Growth Arrest vs Cell Death
2026-09-24
Everolimus (RAD001) inhibits mTOR signaling, but a lower viability signal does not by itself reveal whether cells stopped proliferating or died. This guide applies a dual-outcome framework to mTOR experiments, helping researchers choose measurements and interpret exposure-response data more carefully.
-
AMC-Hem Maps Real-Time HO-1 Activity
2026-09-23
The reference study introduces AMC-Hem, a red-shifted aminocoumarin–heme fluorescence probe designed to report heme oxygenase-1 activity in real time. Its application in primary human macrophages and serum revealed spatially localized activity around erythrocyte-containing lysosomes and identified non-transcriptional regulation of HO-1.
-
Right Ventricular-Like Cardiomyocytes from hPSCs
2026-09-22
Saito et al. developed a differentiation strategy that enriches human pluripotent stem cell-derived cardiomyocytes with right ventricular-like characteristics by modifying mesoderm formation during the GiWi cardiac differentiation protocol. The resulting cells showed SHF-associated molecular identity and functional differences from predominantly left ventricular-like cardiomyocytes, creating a useful platform for chamber-specific disease modeling.
-
Streptavidin Magnetic Beads for RNA Pull-Down
2026-09-22
Learn how Benzyl-activated Streptavidin Magnetic Beads can support biotin-dependent RNA pull-down, interaction mapping, and oncology assay development. This article translates the SNORA38B–E2F1–GAB2 signaling study into practical capture and validation decisions without confusing reagent capability with biological proof.
-
Targeted SPP1 Inhibition in Tumor-Associated Myeloid Cells
2026-09-21
The reference study develops a phenotypic strategy for reducing SPP1 expression in tumor-associated macrophages by combining small-molecule screening with TAM-avid nanodelivery. Its lead formulation, CANDI460, lowered SPP1 in cellular and animal models and produced tumor remissions, providing a framework for therapeutically reprogramming tumor myeloid cells rather than broadly depleting them.
-
AMC-Hem Reveals New HO-1 Regulation
2026-09-21
The reference study introduces AMC-Hem, an aminocoumarin-based fluorescent substrate that enables real-time measurement and imaging of heme oxygenase-1 activity in living cells. Its application to human monocyte-derived macrophages linked HO-1 activity to lysosomal regions around phagocytosed erythrocytes and revealed non-transcriptional regulation by two small molecules.
-
Spatially Concentrated ABEs Correct PLP1 Mutations
2026-09-20
The reference study introduces spatially concentrated adenine base editors that improve pathogenic PLP1 correction in oligodendrocytes by locally enriching the TadA* deaminase near genomic targets. Its compact, AAV-compatible design combines stronger on-target editing with reduced transcriptome-wide RNA off-target activity, providing a mechanistic framework for difficult-to-edit myelinating cells.